Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL CITRATE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL CITRATE versus QDOLO.
FENTANYL CITRATE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent synthetic opioid agonist that primarily acts on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and euphoria. It also interacts with kappa and delta opioid receptors to a lesser extent. By binding to these receptors, fentanyl inhibits adenylate cyclase, reduces cAMP production, closes voltage-gated calcium channels, and opens inwardly rectifying potassium channels, resulting in hyperpolarization and reduced neurotransmitter release.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Initial adult dose 50-100 mcg IV/IM every 1-2 hours as needed for pain; for anesthesia induction 2-20 mcg/kg IV.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life: 3-12 hours (mean 4-6 hours in adults). Context: Prolonged with hepatic impairment, elderly, or continuous infusion (context-sensitive half-life increases with infusion duration).
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Primarily hepatic metabolism (N-dealkylation to norfentanyl and other metabolites); less than 10% excreted unchanged in urine; approximately 9% excreted in feces via biliary elimination.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist